Andrew is VP & Head of Safety Innovation & Analytics at GSK and leads the development of next generation Safety capability as a member of the Global Safety Leadership team. Previously Andrew was in the Global Epidemiology Leadership team at Pfizer and prior to that led the Research function at the Uppsala Monitoring Centre.
Andrew has contributed to many international initiatives and partnerships including membership of the FDA Science Board Subcommittee on Pharmacovigilance, CIOMS VIII on signal detection of adverse effects of medicinal products and Transcelerate Pharmacovigilance Steering Committee where he sponsors the Intelligent Automation work stream. He has served on both the Executive Committee of ISoP and the Board of ISPE.
Andrew holds a Masters degree in Chemistry from Oxford, and a PhD in Clinical Pharmacology on the use of machine learning in pharmacovigilance from Umea University, Sweden. He was a Visiting Professor in Information Systems and Computing, at Brunel University and is an Adjunct Associate Professor in Clinical Pharmacology at NYU Grossman School of Medicine and Honorary Associate Professor of Epidemiology at London School of Hygiene and Tropical Medicine. Andrew has over 100 publications on the analysis of Safety data and RWE generation and his book “Evidence-Based Pharmacovigilance: Clinical and Quantitative Aspects” was published in 2018.